-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 16, the official website of the State Food and Drug Administration showed that Shaanxi Buchang High-tech Pharmaceuticals was approved for production of rivaroxaban tablets for generic type 4 applications and deemed to have been reviewed, becoming the company’s first approved antithrombotic drug.
The total sales of this product in China's public medical institutions and physical pharmacies in cities in China in 2020 will be close to 4 billion yuan
.
Among the varieties under review, apixaban will have global sales of more than 13 billion U.
Rivaroxaban is a highly selective oral anticoagulant that directly inhibits factor Xa developed by Bayer and Johnson & Johnson.
It is used in adult patients with elective hip or knee replacement surgery to prevent venous thrombosis
.
The product has the advantages of good clinical efficacy, convenient administration, no need to adjust dosage and routine monitoring, and its global sales in 2020 will exceed 7 billion U.
Global sales of rivaroxaban
Source: Mynet.
com's sales database of multinational listed companies
According to data from Minai.
com, in recent years, the terminal sales of rivaroxaban tablets in Chinese urban public hospitals, county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies have increased year by year.
In 2020, it will be close to 4 billion yuan, a year-on-year increase of 37.
3%
.
Sales of terminal rivaroxaban in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
In 2020, the sales of terminal rivaroxaban in Chinese urban physical pharmacies exceeded 400 million yuan for the first time.
Among the TOP10 antithrombotic drugs, it ranked third with a market share of about 13%
.
At present, 24 companies have approved the production of rivaroxaban tablets and are deemed to have been reviewed
.
In addition, more than 10 companies have submitted applications for the product's listing under the new classification, which are still under review .
Rivaroxaban tablets are Buchang’s first approved antithrombotic drug.
In the same therapeutic field, the company has another product that has been reported for production.
It is a category 4 generic apixaban tablet.
The original product will be released in 2020.
Annual global sales exceed 13 billion U.
S.
dollars
.
Source: Mi Nei.
com database, official website of the State Drug Administration, etc.
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
